Please login to the form below

Not currently logged in
Email:
Password:

Grunenthal to market MSD’s pain drug

Acquires rights to Arcoxia in several European countries

grunenthal logo Grünenthal has agreed a deal with MSD to market its pain medicine Arcoxia (etoricoxib) in several major European markets.

The agreement covers Grünenthal's home country of Germany, as well as the UK, France, Belgium, Luxemburg, Ireland and Austria. In these countries, Grünenthal will hold exclusive promotion and distribution rights to the COX-2 inhibitor etoricoxib under the brand name Arcoxia.

The drug has been available in Europe via MSD since the early 2000s and is indicated to relieve pain in people with osteoarthritis, rheumatoid arthritis and acute gouty arthritis.

During this time Arcoxia has made a substantial amount of money for MSD - known as Merck & Co in the US and Canada. Just last year it achieved sales of $484m, climbing $30m from 2012.

However, its patents are due to expire soon, and the company has decided it is the right time to divest its interests in certain regions to Grünenthal.

Alberto Grua, chief commercial officer Europe, Australia and North America of Grünenthal, commented that the decision to acquire the rights to Arcoxia in these regions was a boost for the company's pain portfolio.

He said: “By including Arcoxia into our portfolio in select countries, Grünenthal now also offers an innovative therapy option for the treatment of pain with an inflammatory component, which therefore complements our other existing therapy options for the treatment of nociceptive and mixed nociceptive-neuropathic pain.”

Grünenthal's existing pain treatments include Tramal (tramadol).

Article by
Thomas Meek

8th May 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics